Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8141614 | 1.00 | HTR1A (0.50) | HTR1AADRA1BDRD2 | |
| SCHEMBL7851054 | 0.84 | ADRA1B (0.59) | ADRA1B | |
| SCHEMBL8143155 | 0.84 | ADRA1B (0.59) | ADRA1B | |
| SCHEMBL8139000 | 0.84 | ADRA1B (0.59) | ADRA1B | |
| SCHEMBL9458004 | 0.83 | HTR1A (0.65) | HTR1AADRA1BDRD2 | |
| SCHEMBL9457996 | 0.83 | HTR1A (0.65) | HTR1AADRA1BDRD2 | |
| SCHEMBL9812520 | 0.83 | HTR1A (0.65) | HTR1AADRA1BDRD2 | |
| SCHEMBL9457833 | 0.83 | HTR1A (0.65) | HTR1AADRA1BDRD2 | |
| SCHEMBL9457993 | 0.83 | HTR1A (0.65) | HTR1AADRA1BDRD2 | |
| SCHEMBL9458382 | 0.82 | HTR1A (0.54) | HTR1AADRA1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0808318-B1 | TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS | ABBOTT LAB (US) | 2000-06-28 | — | — | EP | disclosed |
| US-5597823-A | TREATING BENIGN PROSTATIC HYPERPLASIA | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | disclosed |
| WO-1996022992-A1 | TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-08-01 | — | — | WO | disclosed |